阿托伐他汀钙片治疗急性冠脉综合征的临床疗效

目的:探讨阿托伐他片汀治疗急性冠脉综合征(ACS)的临床疗效。方法:选择2013年3月至2013年12月我院收治的156例ACS患者,按随机字数表法分为实验组和对照组各78例,两组均采取常规治疗,实验组在此基础上加用阿托伐他汀钙片,对照组则用辛伐他汀滴丸。对比两组治疗效果及心血管事件发生率。结果:两组治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、血清高敏C反应蛋白(hs-CRP)、纤维蛋白原(Fg)和尿酸水平均明显下降,且实验组下降更明显,比较差异均有统计学意义(P0.05);治疗期间实验组心血管事件发生率率为8.97%(7/78),显著低于对照组的24.36%(19/78),比较差异均有统计学意义(P0.05)。结论:阿托伐他汀片治疗ACS的临床效果优于辛伐他汀滴丸,能有效降低心血管事件的发生,值得的临床推广。

Clinical Curative Effect of Atorvastatin in the Treatment of Patients with Acute Coronary Syndrome

Objective:To investigate the effect of atorvastatin in the treatment of patients with acute coronary syndrome.Methods:156 cases of patients with acute coronary syndrome in our hospital from March 2013 to December 2013 were randomly divided into experimental group and control group, each group with 78 cases. The two groups were taken routine treatment, the control group was added with simvastatin, while the experimental group was given atorvastatin in addition. The therapeutic effect and the incidence rate of cardiovascular events of the two groups were compared.Results:The levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), serum high-sensitivity c-reactive protein (hs-CRP), fibrinogen (Fg) and uric acid of the two groups significantly decreased after treatment, and the experimental group decreased more obviously (P<0.05); The incidence rate of cardiovascular events of the experimental group was 8.97% (7/78), significantly lower than 24.36% (19/78) of control group during the treatment period (P<0.05).Conclusion:Atorvastatin in the treatment of patients with acute coronary syndrome has a significant effect compared simvastatin, and can effectively reduce the incidence of cardiovascular events, which is worthy of further clinical application.